

PRESS RELEASE

Caen, France, November 3, 2025

H.A.C. Pharma announces the acquisition of worldwide rights, outside the US, to a rare disease drug from Roche

Aligned with its long-term growth strategy, the French pharmaceutical company H.A.C. Pharma is expanding its footprint across international markets, while consolidating its position in the rare diseases space through the acquisition of worldwide rights, outside the US, to the specialty product ESBRIET® (Pirfenidone) from Roche.

ESBRIET®, active ingredient pirfenidone, is a medicine used for the treatment of adults with idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. “Idiopathic” means that the cause of the disease is unknown.¹

H.A.C. Pharma offers patients a diversified portfolio of essential medicines and life-saving treatments. The group focuses its efforts on four priority areas: rare diseases, onco-hematology, central nervous system and endocrinology.

H.A.C. Pharma is recognized for its work around therapeutic education, supporting both healthcare professionals and patient groups in the diagnosis and understanding of illnesses, treatment options, and therapeutic adherence. To achieve this, H.A.C. Pharma develops new formulations together with compliance tools and deploys a Medical Science Liaison Team to promote the proper use of its medicines. H.A.C. Pharma also directly manages the continuous supply of its product portfolio and leads a pan-European network of distributors.

Along with the founder and majority shareholder, Philippe Bissay, the management team has implemented an intensive search for product acquisitions and innovations in-licensing to expand its portfolio and footprint in Europe and the UK. Supported by Turenne Santé and BNPP Développement, which acquired a stake in the company in January 2022, H.A.C. Pharma wishes to continue expanding its range of products and territories.

Philippe Bissay, Chairman and CEO of H.A.C. Pharma, declares: *“This is a major acquisition that aligns with several promising ongoing in-licensing deal discussions with international biotech companies. It rewards the hard work of our teams and validates our European development strategy, which is based on acquiring proven molecules and launching innovative licensed products.”*

¹ Source EMA

Mounia Chaoui and Sophie Canetos, Turenne Santé, indicate: *"Following an intense year of business development activities in 2025, we are delighted to announce this new acquisition. The product reinforces H.A.C. Pharma's position in rare diseases where the company has strong expertise and will significantly enhance H.A.C. Pharma's international presence."*

Frédéric Connault, BNP PARIBAS Développement, adds: *"We are very pleased with this new acquisition, which marks another significant step in H.A.C. Pharma's transformation into a key European player in hospital and specialty prescription medicines."*

PRESS CONTACTS

Delphine Granier – Turenne Groupe

dgranier@turennecapital.com

+33 6 33 05 48 50

H.A.C. Pharma

communication@hacpharma.com

+33 2 31 47 92 46

ABOUT H.A.C. PHARMA

H.A.C. Pharma is a French independent pharmaceutical laboratory based in Caen. Founded in 2007 by Philippe Bissay, H.A.C. Pharma works to maintain and make available drugs with significant therapeutic added value. H.A.C. Pharma markets prescription drugs in Europe, in various therapeutic areas such as onco-hematology, neurology, psychiatry and endocrinology.

Health actor, present alongside patients and health professionals, H.A.C. Pharma is recognized for promoting the proper use of its pharmaceutical specialties.

H.A.C. Pharma is pursuing its growth strategy in Europe via three areas of development: collaboration with international laboratories for the marketing of their drugs, the acquisition of mature molecules and the launch of innovative products under license.

www.hacpharma.com/en/

ABOUT TURENNE GROUPE

Independent leader in small cap private equity in France, Turenne Groupe has been supporting entrepreneurs for 25 years, via its management companies, in their innovation, development and transfer projects of their company throughout the country.

With more than 2 billion euros in assets under management and +300 companies in its portfolio, Turenne Groupe relies on sectoral expertise with dedicated teams in the health, engineering and environmental services sectors, deeptech, hotels, as well as specific expertise (debt funds and funds with reinforced CSR criteria).

Present throughout France with 7 regional locations (Paris, Lille, Lyon, Marseille, Nice, Bordeaux and Nantes) and regional funds, Turenne Groupe has 85 employees, half of whom are in the region.

A mission-driven company since 2023, and 100% owned by its employees, Turenne Groupe actively supports its portfolio companies in their CSR approach by strongly promoting the sharing of value creation. Turenne Groupe also finances and runs the Béatrice Denys Foundation for therapeutic innovation.

www.turennecapital.com

ABOUT BNP PARIBAS DEVELOPPEMENT

BNP Paribas Développement, an independent subsidiary of the international banking group BNP Paribas, is a public limited company which has, for over 30 years, invested its own funds directly as a minority shareholder to support the development of successful SMEs & ETIs and ensure their sustainability by facilitating their transmission. Beyond the financial resources made available to the company to ensure stable resources, the vocation of BNP Paribas Développement is to support the management team over the long term in carrying out its medium-term strategic projects. Our minority positioning ensures our partners appropriate governance without interference in day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of more than 400 diversified holdings representing more than of €2000 million invested.